JP4412521B2 - ｓＰＬＡ２阻害作用を有するピロロ［１，２−ａ］ピラジン誘導体 - Google Patents

ｓＰＬＡ２阻害作用を有するピロロ［１，２−ａ］ピラジン誘導体 Download PDF

Info

Publication number
JP4412521B2
JP4412521B2 JP2000542326A JP2000542326A JP4412521B2 JP 4412521 B2 JP4412521 B2 JP 4412521B2 JP 2000542326 A JP2000542326 A JP 2000542326A JP 2000542326 A JP2000542326 A JP 2000542326A JP 4412521 B2 JP4412521 B2 JP 4412521B2
Authority
JP
Japan
Prior art keywords
ethyl
pyrazin
methyl
oxamoylpyrrolo
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000542326A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002530268A (ja
JP2002530268A5 (https=
Inventor
光昭 大谷
雅弘 冨士
哲夫 岡田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of JP2002530268A publication Critical patent/JP2002530268A/ja
Publication of JP2002530268A5 publication Critical patent/JP2002530268A5/ja
Application granted granted Critical
Publication of JP4412521B2 publication Critical patent/JP4412521B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2000542326A 1998-03-31 1999-03-31 ｓＰＬＡ２阻害作用を有するピロロ［１，２−ａ］ピラジン誘導体 Expired - Fee Related JP4412521B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP8599798 1998-03-31
JP10-244735 1998-08-31
JP10-85997 1998-08-31
JP24473598 1998-08-31
PCT/JP1999/001670 WO1999051605A1 (en) 1998-03-31 1999-03-31 PYRROLO[1,2-a]PYRAZINE sPLA2 INHIBITOR

Publications (3)

Publication Number Publication Date
JP2002530268A JP2002530268A (ja) 2002-09-17
JP2002530268A5 JP2002530268A5 (https=) 2009-11-12
JP4412521B2 true JP4412521B2 (ja) 2010-02-10

Family

ID=26427020

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000542326A Expired - Fee Related JP4412521B2 (ja) 1998-03-31 1999-03-31 ｓＰＬＡ２阻害作用を有するピロロ［１，２−ａ］ピラジン誘導体

Country Status (11)

Country Link
US (1) US6407104B1 (https=)
EP (1) EP1066290A1 (https=)
JP (1) JP4412521B2 (https=)
KR (1) KR20010042307A (https=)
CN (1) CN1303384A (https=)
AU (1) AU3054399A (https=)
BR (1) BR9909345A (https=)
CA (1) CA2326522A1 (https=)
HU (1) HUP0102981A3 (https=)
NO (1) NO20004881L (https=)
WO (1) WO1999051605A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2023042716A1 (https=) * 2021-09-17 2023-03-23

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6004799A (en) 1998-10-14 2000-05-01 Shionogi & Co., Ltd. Remedies or preventives for ischemic reflow failure
AU6015600A (en) 1999-07-19 2001-02-05 Shionogi & Co., Ltd. Tricyclic compounds having spla2-inhibitory activities
WO2001014378A1 (en) 1999-08-23 2001-03-01 Shionogi & Co., Ltd. PYRROLOTRIAZINE DERIVATIVES HAVING sPLA2-INHIBITORY ACTIVITIES
AU7559600A (en) * 1999-10-15 2001-04-23 Shionogi & Co., Ltd. V type and/or x type spla2 inhibitors
US6756376B1 (en) 1999-11-15 2004-06-29 Shionogi & Co., Ltd. Tricyclic azaindolizine derivatives having an sPLA2-inhibitory activities
US6967200B2 (en) 2000-06-29 2005-11-22 Shionogi & Co., Ltd. Remedies for cirrhosis
WO2002000621A1 (en) * 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Compounds exhibiting x-type spla2 inhibiting effect
AUPQ876400A0 (en) * 2000-07-14 2000-08-03 University Of Queensland, The Compositions and method of using them
WO2002012249A2 (en) * 2000-08-04 2002-02-14 Eli Lilly And Company Substituted pyrrole compounds and their use as spla2 inhibitors
TWI314457B (https=) * 2001-03-19 2009-09-11 Shionogi & Co
US6730694B1 (en) 2001-07-20 2004-05-04 Eli Lilly And Company sPLA2 inhibitors
DE10155727A1 (de) * 2001-11-13 2003-05-28 Morphochem Ag Serin Protease Inhibitoren
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
EP1910385B1 (en) * 2005-08-04 2013-07-24 Sirtris Pharmaceuticals, Inc. Benzothiazoles and thiazolopyridines as sirtuin modulators
TW200916472A (en) * 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
NZ624963A (en) 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
CN105622616A (zh) * 2016-02-25 2016-06-01 上海雅本化学有限公司 一种4-氯吡咯并嘧啶的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
IL109311A0 (en) 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
BR9501404A (pt) 1994-04-01 1996-03-05 Lilly Co Eli 1H-indol-3 glioxilamida e formulação farmacèutica
US5641800A (en) 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
BR9508298A (pt) * 1994-07-21 1998-11-03 Shionogi & Co Inibidores de indolizina de spla2
US6214876B1 (en) * 1994-07-21 2001-04-10 Eli Lilly And Company Indene-1-acetamide sPLA2 inhibitors
ES2174034T3 (es) 1995-12-13 2002-11-01 Lilly Co Eli Naftilglioxamidas como inhibidores de spla2
EP0779271B1 (en) 1995-12-13 2001-08-01 Eli Lilly And Company Naphthyl acetamides as sPLA2 inhibitors
CA2269203A1 (en) 1996-10-30 1998-05-07 Nicholas James Bach Substituted tricyclics
US5916922A (en) 1996-12-03 1999-06-29 Eli Lilly And Company Phenyl glyoxamides as SPLA2 inhibitors
US6353128B1 (en) 1996-12-03 2002-03-05 Eli Lilly And Company Phenyl acetamides as sPLA2 inhibitors
ID18983A (id) 1996-12-04 1998-05-28 Lilly Co Eli Pirazola sebagai inhibitor sekresi fosfolipase a2 non-pankreas pada manusia
US5919774A (en) 1996-12-10 1999-07-06 Eli Lilly And Company Pyrroles as sPLA2 inhibitors
TW455581B (en) 1997-06-26 2001-09-21 Lilly Co Eli Process for preparing 4-substituted-1H-indole-3-glyoxamides

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2023042716A1 (https=) * 2021-09-17 2023-03-23
WO2023042716A1 (ja) * 2021-09-17 2023-03-23 三井化学株式会社 （メタ）アクリルアミド化合物の製造方法
JP7696436B2 (ja) 2021-09-17 2025-06-20 三井化学株式会社 （メタ）アクリルアミド化合物の製造方法

Also Published As

Publication number Publication date
CA2326522A1 (en) 1999-10-14
JP2002530268A (ja) 2002-09-17
AU3054399A (en) 1999-10-25
NO20004881L (no) 2000-11-28
US6407104B1 (en) 2002-06-18
BR9909345A (pt) 2000-12-12
NO20004881D0 (no) 2000-09-28
WO1999051605A1 (en) 1999-10-14
EP1066290A1 (en) 2001-01-10
HUP0102981A3 (en) 2002-10-28
CN1303384A (zh) 2001-07-11
KR20010042307A (ko) 2001-05-25
HUP0102981A2 (hu) 2002-01-28

Similar Documents

Publication Publication Date Title
JP4544446B2 (ja) ｓＰＬＡ２阻害作用を有するピロロ［１，２−ｂ］ピリダジン誘導体
JP4623483B2 (ja) ｓＰＬＡ２阻害作用を有するピロロトリアジン誘導体
JP4412521B2 (ja) ｓＰＬＡ２阻害作用を有するピロロ［１，２−ａ］ピラジン誘導体
JPWO1999059999A1 (ja) ｓＰＬＡ２阻害作用を有するピロロ［１，２−ｂ］ピリダジン誘導体
JPWO2001014378A1 (ja) ｓＰＬＡ２阻害作用を有するピロロトリアジン誘導体
JP5680146B2 (ja) Ｃｒｔｈ２受容体拮抗薬としての複素環化合物
JP4972644B2 (ja) Ｃｒｔｈ２受容体拮抗薬としてのインドール誘導体
AU753547B2 (en) Substituted tricyclics
EA020816B1 (ru) Ингибиторы вирусов flaviviridae
CN101484449A (zh) 整合酶抑制剂-3
HK1054034B (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
CN111566102A (zh) 作为激活素受体样激酶抑制剂的取代的吡咯并吡啶
US20030181454A1 (en) Compounds exhibiting x-type spla2 inibiting effect
US6756376B1 (en) Tricyclic azaindolizine derivatives having an sPLA2-inhibitory activities
TW202506666A (zh) Ｉｌ－１７ａ的小分子調節劑、其製備方法和使用方法
JPH09510700A (ja) エンケファリナーゼ阻害剤として有用な新規なインダン−２−メルカプトアセチルアミドジスルフィド誘導体類
JP4636521B2 (ja) ｓＰＬＡ２阻害作用を有する三環系化合物
JP4636522B2 (ja) ｓＰＬＡ２阻害作用を有する三環式化合物
JPWO2001005789A1 (ja) ｓＰＬＡ２阻害作用を有する三環系化合物
JPWO2001009130A1 (ja) ｓＰＬＡ２阻害作用を有する三環式化合物
JP5841361B2 (ja) 三環性化合物及びそれを含有する医薬組成物
JPWO2001036420A1 (ja) ｓＰＬＡ２阻害作用を有する三環性アザインドリジン誘導体
MXPA00011018A (en) PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES HAVING sPLA2
CZ20003193A3 (cs) Sloučenina pyrrolo[l,2-a]pyrazinu, proléčivo, farmaceutický prostředek a metoda inhibující sPLA2
MXPA00009418A (en) PYRROLO[1,2-a]PYRAZINE sPLA2

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090804

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20090917

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20091110

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20091111

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121127

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees